What is the appropriate second‑line maintenance therapy for a patient with advanced non‑small cell lung cancer who has completed 4‑6 cycles of platinum‑based induction chemotherapy, has stable disease and recovered from toxicities, and whose tumor is non‑squamous without EGFR mutation, squamous, or EGFR‑mutated?

Second-Line Maintenance Therapy for Advanced NSCLC

The question appears to conflate "second-line therapy" with "maintenance therapy"—these are distinct treatment paradigms that should not be confused, as maintenance therapy occurs after first-line induction (before progression), while second-line therapy begins after documented disease progression.

Critical Distinction: Maintenance vs. Second-Line Therapy

Maintenance therapy is administered to patients who have NOT progressed after 4-6 cycles of platinum-based chemotherapy, while second-line therapy is given after documented progression. 1 These are fundamentally different clinical scenarios with different treatment algorithms.

If the Question is About MAINTENANCE Therapy (After First-Line, Before Progression):

For Non-Squamous NSCLC (EGFR Mutation-Negative or Unknown):

Continuation maintenance options:

• Bevacizumab (Category 1) - continue if used in first-line 1
• Cetuximab (Category 1) - continue if used in first-line 1
• Pemetrexed - if used in first-line cisplatin/pemetrexed regimen (PARAMOUNT trial: OS HR 0.78, PFS HR 0.64) 1, 2
• Gemcitabine - if used in first-line 1

Switch maintenance options:

• Pemetrexed - demonstrated OS benefit (15.5 vs 10.3 months, P=0.002) in non-squamous histology 1
• Erlotinib - demonstrated OS benefit (12 vs 11 months, HR 0.81) with greatest benefit in stable disease patients 1

For Squamous Cell Histology:

Continuation maintenance:

• Cetuximab (Category 1) 1
• Gemcitabine 1

Switch maintenance:

• Erlotinib 1
• Docetaxel (Category 2B) - lower recommendation due to trial design limitations 1

For EGFR-Mutated Tumors:

EGFR-TKI therapy (erlotinib, gefitinib, or afatinib) should be the preferred first-line treatment, not maintenance therapy. 1 If not given first-line, these agents should be administered at any subsequent line. 1

If the Question is About TRUE SECOND-LINE Therapy (After Progression):

For Non-Squamous NSCLC After Progression:

First choice: Immune checkpoint inhibitors (for PS 0-2, no actionable mutations):

• Nivolumab or atezolizumab (regardless of PD-L1 expression) 2
• Pembrolizumab (if PD-L1 ≥1%) 2

Second choice: Single-agent chemotherapy:

• Pemetrexed monotherapy (non-squamous only) - median survival 4-5 months 1, 2
• Docetaxel (all histologies) 1, 2

Alternative options:

• Nintedanib plus docetaxel (adenocarcinoma) 2
• Ramucirumab plus docetaxel 2
• Erlotinib (if EGFR status unknown or wild-type, PS 0-3) 1

Critical Pitfalls to Avoid:

• Do not confuse maintenance with second-line therapy - maintenance occurs before progression, second-line after progression 3, 4
• Pemetrexed evidence in non-squamous NSCLC applies to maintenance, not re-treatment after progression 2
• Molecular testing (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, PD-L1) must be completed before second-line therapy, as targeted therapy supersedes chemotherapy 2
• Continuation beyond 4-6 cycles of full-intensity platinum doublets shows no OS benefit and increases toxicity 1
• Observation remains a valid option for maintenance if patients prefer a treatment break 1